Scientists discover why Ozempic works better for some peopleScientists discover why Ozempic works better for some people
Some people taking Ozempic-like diabetes drugs may be getting dramatically better results for a surprising reason: why they overeat in the first place. A year-long study in Japan found that people who tend to eat because tempting food looks or smells irresistible were much more likely to lose weight and improve blood sugar levels on Read More
Common inflammatory genes link pancreatic cancer with obesity and diabetesCommon inflammatory genes link pancreatic cancer with obesity and diabetes
New research shows that the same genes are active in pancreatic cancer, obesity and diabetes, helping to explain why people with metabolic disease often face poorer cancer outcomes and pointing to future ways to predict recurrence and develop more targeted treatments.
Stopping GLP-1 drugs can quickly erase cardiovascular benefitsStopping GLP-1 drugs can quickly erase cardiovascular benefits
Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits. However, when patients stop taking these drugs, they not only regain weight, but, according to a new study, they also incur Read More
New study identifies how obesity-related liver cancer becomes more aggressive and resistant to treatmentNew study identifies how obesity-related liver cancer becomes more aggressive and resistant to treatment
A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. The study reveals that a specific signaling pathway involving endotrophin—a protein secreted during liver fibrosis—and the receptor protein CD44 promotes tumor malignancy and drug resistance.
GLP-1 drugs and pregnancy: Who may face higher preterm birth riskGLP-1 drugs and pregnancy: Who may face higher preterm birth risk
Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes. However, a large study of over 750,000 pregnancies found that there was no link to preterm births or other obstetric complications if the medication was being Read More
Discussing Recurrence Risk and Survivorship in Breast CancerDiscussing Recurrence Risk and Survivorship in Breast Cancer
(MedPage Today) — In “Beyond Diagnosis: Breast Cancer,” Cleveland Clinic oncologist Tiffany Onger, MD, and host John Mangels continue their conversations on communicating effectively and empathetically with patients across the breast cancer care…
WH Chief of Staff Susie Wiles Diagnosed With Breast CancerWH Chief of Staff Susie Wiles Diagnosed With Breast Cancer
White House chief of staff Susie Wiles announced on Monday that she has been diagnosed with breast cancer in the past week. She said she will continue to remain at the White House during her unspecified treatment. NBC’s Kelly O’Donnell reports for TODAY.
Opinion: Semaglutide is going off-patent in India. But will people who need it be able to get it?Opinion: Semaglutide is going off-patent in India. But will people who need it be able to get it?
She is 53, “normal” weight, and has already had a heart attack. A drug proven to prevent the next one becomes affordable in her country. But she can’t access it because of a line drawn for someone else, on another continent. A billion people are about to fall on the wrong side of it. Read Read More
Susie Wiles to stay on as White House chief of staff amid breast cancer treatmentSusie Wiles to stay on as White House chief of staff amid breast cancer treatment
White House chief of staff Susie Wiles has been diagnosed with early-stage breast cancer, she confirmed on Monday. CBS News medical contributor Dr. Céline Gounder joins “The Takeout” to discuss further.
GLP-1 Drugs Show Growing Promise for Afib ControlGLP-1 Drugs Show Growing Promise for Afib Control
(MedPage Today) — For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested. People who came out of catheter ablation… (MedPage Today) — For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the Read More